Transactions
13
Insider / AGIOS PHARMACEUTICALS, INC.
Scadden David
Director at AGIOS PHARMACEUTICALS, INC.
- Company
- AGIOS PHARMACEUTICALS, INC.
- Ticker
- AGIO
- First filing on record
- October 2, 2025
- Latest trade on record
- June 18, 2026
- SEC filings
- EDGAR ↗
Scadden David, Director at AGIOS PHARMACEUTICALS, INC., has disclosed 13 transactions in AGIO since October 2, 2025: 0 purchases (0 open-market buys) and 3 sales, worth about $36K at the reported prices. The latest was filed June 23, 2026, 5 days after the trade; 4 filings were late against the 2-business-day Form 4 deadline.
Open-market buys
0
Sales
3
Avg. disclosure lag
2.9d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Scadden David made no purchases and 1 sale worth $9K, plus 6 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Scadden David has traded 1 stock on record; the largest by dollars is AGIO.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
1 of 4 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| M | Option exercise or conversion | 8 | 6,832 | $11K |
| S | Open-market sale | 3 | 600 | $25K |
| A | Grant or award | 2 | 17,877 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 4 | 0 | 0 |
| 2025 | 9 | 0 | 3 · $25K |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| AGIO | Other A | June 18, 2026 | June 23, 2026 | 5d | 14,950 | — | — | latederivative | Form 4 ↗ | |
| AGIO | Other A | June 18, 2026 | June 23, 2026 | 5d | 2,927 | — | — | latederivative | Form 4 ↗ | |
| AGIO | Option / conversion M | June 18, 2026 | June 23, 2026 | 5d | 2,816 | — | — | latederivative | Form 4 ↗ | |
| AGIO | Option / conversion M | June 18, 2026 | June 23, 2026 | 5d | 2,816 | — | — | late | Form 4 ↗ | |
| AGIO | Option / conversion M | November 12, 2025 | November 14, 2025 | 2d | 200 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| AGIO | Sell S | November 12, 2025 | November 14, 2025 | 2d | 200 | $44 | $8,768 | 10b5-1 plan | Form 4 ↗ | |
| AGIO | Option / conversion M | November 12, 2025 | November 14, 2025 | 2d | 200 | $18 | $3,618 | 10b5-1 plan | Form 4 ↗ | |
| AGIO | Option / conversion M | October 8, 2025 | October 10, 2025 | 2d | 200 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| AGIO | Sell S | October 8, 2025 | October 10, 2025 | 2d | 200 | $41 | $8,200 | 10b5-1 plan | Form 4 ↗ | |
| AGIO | Option / conversion M | October 8, 2025 | October 10, 2025 | 2d | 200 | $18 | $3,618 | 10b5-1 plan | Form 4 ↗ | |
| AGIO | Option / conversion M | September 30, 2025 | October 2, 2025 | 2d | 200 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| AGIO | Sell S | September 30, 2025 | October 2, 2025 | 2d | 200 | $40 | $8,000 | 10b5-1 plan | Form 4 ↗ | |
| AGIO | Option / conversion M | September 30, 2025 | October 2, 2025 | 2d | 200 | $18 | $3,618 | 10b5-1 plan | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| June 23, 2026 | Form 4 | 0001439222-26-000095 | 4 | published | EDGAR ↗ |
| November 14, 2025 | Form 4 | 0001439222-25-000120 | 3 | published | EDGAR ↗ |
| October 10, 2025 | Form 4 | 0001439222-25-000108 | 3 | published | EDGAR ↗ |
| October 2, 2025 | Form 4 | 0001439222-25-000106 | 3 | published | EDGAR ↗ |
Other insiders at AGIOS PHARMACEUTICALS, INC.
- Gheuens Sarah Chief Medical Officer 39 rows
- Goff Brian Chief Executive Officer 25 rows
- Burns James William Chief Legal Officer 22 rows
- Jones Cecilia Chief Financial Officer 22 rows
- Milanova Tsveta Chief Commercial Officer 19 rows
- Washburn Theodore James Jr. Principal Accounting Officer 11 rows
- Viswanadhan Krishnan Chief Corp Dev & Strategy 10 rows
- CAPELLO JEFFREY D Director 6 rows
- Owen Adams Catherine Director 6 rows
- Backstrom Jay T. Director 4 rows
Everyone on file, with contracts and lobbying under the company's name: AGIOS PHARMACEUTICALS, INC..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Rule 10b5-1 trading plans The plan must be set up when the insider has no important non-public information.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 4 | 13 | October 2, 2025 | June 23, 2026 | Form 4 list on EDGAR |
Site built October 27, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.